Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001764013-25-000124
Filing Date
2025-07-30
Accepted
2025-07-30 17:56:29
Documents
2
Period of Report
2025-07-28

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1753912582.html 4  
1 FORM 4 wk-form4_1753912582.xml 4 9754
2 EX-24.1 immunovant-section16poaxer.htm EX-24.1 8569
  Complete submission text file 0001764013-25-000124.txt   19875
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Issuer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 6TH FLOOR NEW YORK NY 10018
Business Address
Venker Eric (Reporting) CIK: 0001801917 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38906 | Film No.: 251168430